Equity Overview
Price & Market Data
Price: $7.31
Daily Change: -$0.02 / 0.27%
Daily Range: $7.02 - $8.44
Market Cap: $489,692,952
Daily Volume: 357,799
Performance Metrics
1 Week: 5.48%
1 Month: -9.31%
3 Months: -13.70%
6 Months: -17.40%
1 Year: 56.53%
YTD: -19.58%
Company Details
Employees: 82
Sector: Commercial services
Industry: Miscellaneous commercial services
Country: Canada
Details
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada.